Latest Breaking News On - Re evaluating conditions - Page 1 : comparemela.com

Atossa Therapeutics Announces First Quarter 2024 Financial

Atossa Therapeutics Announces First Quarter 2024 Financial
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesEric van zantenTessa ciglerEli lillyAtossa therapeutics incWeill cornell breast centerExchange commissionDevelopment expenseOestrogen receptorHuman epidermal growth factor receptorRe evaluating conditionsActive surveillance suitabilityDuctal carcinoma in situSteven quayChief executive

Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update

Fully enrolled two Phase 2 studies with data from both expected in the second half of 2024First patient dosed in new Phase 2 breast cancer prevention studyData from ongoing Phase

United statesNew yorkJonathan finnTessa ciglerEric van zantenMatthew goetzDevelopment expenseAtossa therapeutics incWeill cornell breast centerMayo clinic women cancer programAmerican association for cancer researchMayo clinic comprehensive cancer centerAustralian taxation officeExchange commissionVantage consulting groupEndoxifen clinical trial

Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update

Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesMatthew goetzEric van zantenJonathan finnTessa ciglerWeill cornell breast centerExchange commissionAustralian taxation officeAmerican association for cancer researchVantage consulting groupMayo clinic comprehensive cancer centerDevelopment expenseAtossa therapeutics incMayo clinic women cancer programEndoxifen clinical trial

Atossa Therapeutics Announces First Patient Dosing of (Z)-Endoxifen in the Ongoing RECAST DCIS Study

SEATTLE, Feb. 22, 2024 (GLOBE NEWSWIRE) Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in oncology with a focus on breast cancer, today announced that the first patient has been dosed with Atossa’s proprietary Selective Estrogen Receptor Modulator (SERM), (Z)-endoxifen, in the Re-Evaluating Conditions for Active Surveillance Suitability as Treatment: Ductal Carcinoma In Situ (R

United statesSan franciscoEric van zantenUniversity of californiaAtossa therapeutics incSelective estrogen receptor modulatorRe evaluating conditionsActive surveillance suitabilityDuctal carcinoma in situCarcinoma in situSteven quayChief executiveQuantum leap healthcare collaborativeSilicon valleyLeap healthcare collaborativeBreast cancer

Atossa Therapeutics doses first patient with (Z)-endoxifen in Phase 2 breast cancer trial

Atossa Therapeutics doses first patient with (Z)-endoxifen in Phase 2 breast cancer trial
proactiveinvestors.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com Daily Mail and Mail on Sunday newspapers.

Atossa therapeutics incRe evaluating conditionsActive surveillance suitabilityDuctal carcinoma in situSteven quay